Mark Erlander - 11 Mar 2025 Form 4 Insider Report for Cardiff Oncology, Inc. (CRDF)

Role
Chief Executive Officer, Director
Signature
/s/ Mark Erlander
Issuer symbol
CRDF
Transactions as of
11 Mar 2025
Net transactions value
$0
Form type
4
Filing time
13 Mar 2025, 16:02:02 UTC
Previous filing
07 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRDF Stock Options Award $0 +758,400 +35% $0.000000 2,925,098 11 Mar 2025 Common Stock 758,400 $3.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option will vest on March 11, 2026 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the continued service of the reporting person.